✦ LIBER ✦

364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer

✍ Scribed by T. Shimizu; A.W. Tolcher; P. LoRusso; K. Papadopoulos; A. Patnaik; L. Smith; M. Keegan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

590 Final Results of a Phase Ib Study of

✍ Voi, M.; Fu, S.; Nemunaitis, J.; Bauman, J.; Bessudo, A.; Hamid, O.; Witta, S.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A phase I, first-in-human dose-escalatio

✍ Raoul Tibes, Gil Fine, Gavin Choy, Sanjeev Redkar… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 232 KB

2118 POSTER A phase I study of trastuzum

✍ I.E. Krop; M. Beeram; S. Modi; N. Rabbee; S. Girish; J. Tibbitts; S.N. Holden; S 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

A first in human phase I study of the pr

✍ Gallerani, Elisa; Zucchetti, Massimo; Brunelli, Dario; Marangon, Elena; Noberasc 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 365 KB

Phase I and pharmacokinetic/pharmacodyna

✍ Kazunori Honda, Noboru Yamamoto, Hiroshi Nokihara… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 242 KB

A first-in-class, first-in-human, phase

✍ Warso, M A; Richards, J M; Mehta, D; Christov, K; Schaeffer, C; Rae Bressler, L; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 748 KB